Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli said,

Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 billion deal will not raise competitive concerns.

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,

U.S. consumer groups and labor unions are urging the FTC to block Novo Holdings' acquisition of Catalent. They argue it could stifle competition for weight loss drugs and gene therapies, affecting companies like Amgen and Pfizer.

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk , from acquiring contract drug manufacturer Catalent ,

U.S. consumer groups and labor unions have called on the Federal Trade Commission to block Novo Holdings from acquiring Catalent, a contract drug manufacturer. Concerns focus on competition in weight-loss drugs and gene therapies.